跳至主要内容
临床试验/NCT02576587
NCT02576587已完成不适用

Elucidation of the Influence of Sleep Apnea on Risk of Atrial Fibrillation

The Cleveland Clinic2 个研究点 分布在 1 个国家目标入组 317 人开始时间: 2012年1月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
317
试验地点
2
主要终点
Number of Participants With Paroxymal Atrial Fibrillation (PAF)

研究概览

简要总结

The Elucidation of the Influence of Sleep Apnea on Risk of Atrial Fibrillation study.

The study involves a case control design to investigate the extent to which there is an independent relationship of sleep disordered breathing (SDB) and paroxysmal atrial fibrillation (PAF). Cases will be defined as clinically identified patients with PAF and controls as those without AF. In order to rigorously address important biologic confounding influences, the cases and controls will be individually matched based upon age, gender, race, and body mass index. Those participants with both PAF and SDB (Apnea Hypopnea Index, AHI>=15) will be asked to return for a follow up exam after 3 months of SDB treatment in the Clinical Research Unit (CRU) for collection of the same measures collected at the baseline exam to observe for any significant changes with the purpose of collecting effect size data to inform future clinical trials.

The total duration of the study is 4 years. The duration for any individual participant is up to from one to 13 weeks months, including a 3-month treatment period for those with moderate to severe SDB, i.e. AHI>15.

详细描述

Sleep-disordered breathing (SDB) is common in patients with cardiovascular disease and its attendant hypoxemia and autonomic dysfunction create a milieu that is likely to enhance AF propensity. Thus, SDB may represent a novel target for AF prevention and treatment strategies. Although our prior cross-sectional work has shown a 2-4 fold higher odds of AF related to SDB, these and other reports have not included cardiac structural data or autonomic/biochemical measures, and have addressed only arrhythmic events occurring during an overnight sleep study. In this proposal, we will examine paroxysmal AF (PAF), an early stage risk factor for persistent AF, and relevant to this proposal because it occurs prior to extensive cardiac electrical remodeling/fibrosis.

OUTLINE OF STUDY VISITS Baseline Visit (SA 1 and 2). After informed consent, eligible participants will be scheduled to arrive for an overnight visit in the CRU. During the evening, participants will undergo questionnaire administration, blood pressure measurements, and anthropometry. They will be provided dinner and undergo polysomnography (PSG). In the morning, participants will undergo fasting venipuncture, overnight urine collection, ECHO, 6 minute walk test, vascular measures and blood pressure measurements. For those with PAF (cases), hook-up for continuous ECG monitoring will be performed along with education regarding how to handle the device and bathing instructions, etc. All measurements in the DCRU/CRU will be performed blinded to PAF status. The only unblinded staff will be a dedicated research assistant who will perform the ECG monitoring hook-up. Blinded staff will collect and process data and perform data entry. After the baseline visit, participants with PAF (n=150) will undergo hook-up of the ECG monitor and an activity monitor at the baseline visit to wear for a 7-21 day period.

Follow-Up Visit (SA3). Those with SDB (AHI>=15) without evidence of central apnea (central apnea index>5) or Cheyne Stokes Respirations via baseline visit PSG and who have PAF will undergo the following. A 5-7 day home-based auto-titration (APAP, Respironics Autopap System One with humidifier) to identify the optimal positive airway pressure (PAP) setting will be performed (with settings 4-20cm H2O). At the end of the 5-7 day titration, the goal will be to identify the pressure that results in an AHI<5 events/hour (optimally). The research assistant will re-set the device to deliver this optimal fixed pressure identified by the PI through the secure wireless web-site. An overnight DCRUCRU visit will be scheduled after 3 months of wearing CPAP during which the same measures performed at the baseline visit will be collected.

STUDY PROCEDURES 2-DIMENSIONAL DOPPLER ECHOCARDIOGRAPHY. Parasternal, apical and subcostal 2-D views and apical 3D views will be obtained with transducer orientation and gain settings adjusted to optimally define endocardial surface of each cardiac chamber.

POLYSOMNOGRAPHY (PSG). Procedure for PSG: Research PSG will be performed using the Compumedics E-series system (Abbottsford, AU) which will include 3 cortical encephalograms, bilateral electro-oculograms, a bipolar submental electromyogram, thoracic and abdominal respiratory inductance plethysmography, airflow (by nasal-oral thermocouple and nasal cannula pressure recording), oximetry (using highly sensitive finger pulse oximeter, sampling frequency 25Hz), electrocardiogram (ECG) at 250Hz (used to derive HRV measures of autonomic function); body position (mercury switch sensor), bilateral leg movements. EEGs are recorded at 125Hz. 3) 7-21 Day CONTINUOUS ECG MONITORING.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Inclusion Criteria for Cases:
  • PAF defined by recurrent episodes of AF, which self-terminate within a 7-day period (based upon AHA consensus statement 77)
  • Age 18-80 years
  • Individuals able to participate in > 2 overnight/daytime sleep and physiologic assessments over a 3 month period.
  • Inclusion Criteria for Controls:
  • Age 18 to 80 years
  • Individuals in normal sinus rhythm (NSR) with no current AF or history of AF
  • Individuals able to participate in an overnight/daytime sleep and physiologic assessment.

排除标准

  • Exclusion Criteria for Cases:
  • PAF with rapid or uncontrolled rate (>120bpm)
  • Post-operative PAF
  • History of cardiac ablation or successful electro-cardioversion for PAF (ablation for other arrhythmias such as AVNRT and if PAF persists after cardioversion is acceptable )
  • Valvular stenosis, prosthesis or significant valvular insufficiency [i.e. those with moderate or greater severity of aortic stenosis (aortic valve area <1.5 cm2), mitral regurgitation which is moderate or more severe in degree (>20% regurgitant fraction) or moderate or greater severity mitral stenosis (mitral valve area <1.5 cm2)]
  • Atrial septal defect
  • Infiltrative/restrictive cardiomyopathy
  • Sick sinus syndrome
  • Previously diagnosed SDB on specific SDB treatments (CPAP, oral appliances)
  • Severe chronic insomnia
  • Circadian rhythm disorder (e.g. shift work sleep disorder, delayed or advanced sleep phase syndrome)
  • Insufficient sleep syndrome defined by reported sleep duration < 4 hrs
  • Supplemental oxygen use
  • Unstable medical conditions (e.g., new onset or changing angina, a myocardial infarction or congestive heart failure exacerbation documented within the previous 3 months, systolic heart failure (Left Ventricular Ejection Fraction < 35%), high grade cardiac dysrhythmia/heart block, stroke with functional limitations, uncontrolled hypertension (BP>170/110), abdominal aneurysm >5.5 cm or >1 cm growth/year, uncontrolled diabetes mellitus (HbA1c>9.0), pulmonary hypertension, non-skin cancer diagnosis or treatment within the previous year, end stage renal and hepatic failure, immunodeficiencies (HIV, HCV), uncontrolled hypo- or hyperthyroidism)
  • Psychiatric disorders which are inadequately treated
  • Compromised competence
  • Alcohol abuse (currently drinks >5 alcoholic drinks/day)
  • Inability to provide informed consent
  • Illicit drug use over last 6 months
  • Rate controlling anti-arrhythmic medication (Classes I-III and V) with no further clinical occurrence of PAF
  • Has a Pacemaker or Implantable cardioverter-defibrillator.
  • Rationale for criteria: The goal of this study is to include those patients with PAF that is not secondary to the post-operative period or valvular disease and without ablation as these processes would result in alteration of atrial physiology and preclude assessment of independent SDB effects on AF which is independent of these conditions. Patients with sleep disorders will be excluded as sleep disorders may influence arrhythmogenesis. Those on treatment for SDB will be excluded because treatment would preclude assessment of SDB pathophysiologic effects on atrial arrhythmogenesis. Those with unstable medical conditions or rapid or uncontrolled heart rate will be excluded due to safety reasons.
  • Note: Exclusion criteria for positive airway pressure (PAP) intervention: Central Apnea Index>5 noted on baseline examination sleep study or evidence of Cheyne Stokes Respirations/periodic breathing (cyclical crescendo and decrescendo change in breathing amplitude).
  • Exclusion Criteria for Controls:
  • Current or history of AF, otherwise the same exclusion criteria listed for cases.

研究组 & 干预措施

Case (diagnosed with PAF)

Other

Cases. Patients with Paroxysmal Atrial Fibrillation who present to Electrophysiology Clinic at UHCMC and the Cleveland Clinic Foundation will be approached for recruitment in the study.

Cases found to have an apnea hypopnea index >=15 will be asked to continue in the study for 3 months wearing a Continuous Positive Airway Pressure (CPAP) machine.

干预措施: Continuous Positive Airway Pressure (Other)

Controls

No Intervention

Controls. Patients without AF will be recruited from General Cardiology and Internal Medicine clinics (geographically similar to controls). Selection bias will be minimized as there are a broad range of reasons for patients to present to these clinics.

结局指标

主要结局

Number of Participants With Paroxymal Atrial Fibrillation (PAF)

时间窗: Baseline

Patients with diagnosis of PAF were defined as cases. PAF is the primary outcome of baseline analysis, which aimed to quantify the association of sleep apnea and PAF.

次要结局

  • Echocardiographic Measures- LA Volume Index(Baseline and 12 week follow up)
  • Echocardiographic Measures- LA Systolic Strain by A2C View(Baseline and 12 week follow up)
  • Vascular Measures- Augmentation Index(Baseline and 12 week follow up)
  • Echocardiography Measures- Left Atrial Volume(Baseline and 12 week follow up)
  • Echocardiographic Measures- LA Systolic Strain by A4C View(Baseline and 12 week follow up)
  • Vascular Measures- Pulse Wave Velocity(Baseline and 12 week follow up)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Reena Mehra, MD

Director of Sleep Disorders Reseach, Associate Professor of Medicine

The Cleveland Clinic

研究点 (2)

Loading locations...

相似试验